Shares of Telik, Inc. (TELK) were up over 30 percent today on news that the company had entered into a definitive merger agreement with MabVax Therapeutics. Investors had never fully fully ...

Telik, Inc. has announced that its library of diverse profiled compounds now exceeds 3.3 million. The expanded library significantly enhances Telik's patented drug discovery technology, Target Related ...

PALO ALTO, Calif., Jan. 11, 2013 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) was notified today that its product candidate, ezatiostat HCL (Telintra), has been granted orphan drug designation by the US ...

All the Telik (NASDAQ:TELK) critics, including myself, got a little egg on their faces today when the drugmaker announced that the FDA had removed the partial hold it had put on the development of its ...

SAN DIEGO, July 9, 2014 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held cancer immunotherapy company, and Telik, Inc. (Nasdaq: TELK), a publicly-traded clinical stage oncology drug ...

MabVax Therapeutics, Inc., a privately held cancer immunotherapy company and Telik, Inc. (Nasdaq: TELK), aclinical stage oncology drug development company have entered into a definitive merger ...

Telik Announces Clinical Hold on TELCYTA Trials PALO ALTO, Calif., June 04, 2007 -- Telik, Inc. announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the ...

Ladies and gentlemen, thank you for standing by. Welcome to the Telik 2008 second quarter earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a ...

management on Wednesday night’s quarterly conference call. That’s not necessarily surprising, but it is disappointing. After all, Telik CEO Michael Wick and Chief Medical Officer Gail Brown (who’s ...

On the heels of an encouraging meeting with the FDA regarding Phase III trials of the company's drug for ovarian cancer and non-small-cell lung cancer, Telik Inc. said it plans to pull down cash ...

Telik Inc. shares fell 70% yesterday, plummeting from $11.49 to $4.77, after the company said its lead cancer drug candidate, Telcyta, failed three late-stage trials. Telcyta didn't prolong survival ...